share_log

Azitra | 10-Q: Q3 2024 Earnings Report

Azitra | 10-Q: Q3 2024 Earnings Report

Azitra | 10-Q:2024財年三季報
美股SEC公告 ·  2024/11/12 22:08

牛牛AI助理已提取核心訊息

Azitra reported Q3 2024 financial results with a net loss of $1.0 million compared to $1.9 million in Q3 2023. Revenue was nil versus $310,700 in the prior year period, while operating expenses increased 27% to $2.9 million driven by clinical program advancement. Cash and equivalents stood at $7.3 million as of September 30, 2024.The company achieved significant clinical milestones, including dosing the first patient in August 2024 for its Phase 1b trial of ATR-12 in Netherton syndrome, with initial safety results expected in Q1 2025. Additionally, Azitra received FDA Fast Track designation for ATR-04 in September 2024 and plans to commence a Phase 1b trial for cancer patients undergoing EGFRi therapy in Q4 2024.Research and development expenses rose 85% to $1.0 million as the company advanced its clinical programs. Management noted substantial doubt about the company's ability to continue as a going concern, citing the need for additional capital to fund operations over the next 12 months. The company completed a follow-on offering in July 2024 raising $9.1 million through the sale of common stock and warrants.
Azitra reported Q3 2024 financial results with a net loss of $1.0 million compared to $1.9 million in Q3 2023. Revenue was nil versus $310,700 in the prior year period, while operating expenses increased 27% to $2.9 million driven by clinical program advancement. Cash and equivalents stood at $7.3 million as of September 30, 2024.The company achieved significant clinical milestones, including dosing the first patient in August 2024 for its Phase 1b trial of ATR-12 in Netherton syndrome, with initial safety results expected in Q1 2025. Additionally, Azitra received FDA Fast Track designation for ATR-04 in September 2024 and plans to commence a Phase 1b trial for cancer patients undergoing EGFRi therapy in Q4 2024.Research and development expenses rose 85% to $1.0 million as the company advanced its clinical programs. Management noted substantial doubt about the company's ability to continue as a going concern, citing the need for additional capital to fund operations over the next 12 months. The company completed a follow-on offering in July 2024 raising $9.1 million through the sale of common stock and warrants.
Azitra報告了2024年第三季度的財務結果,淨虧損爲100萬美元,相較於2023年第三季度的190萬美元。營業收入爲零,而去年同期爲310,700美元,營業費用因臨牀項目推進增長了27%,達到290萬美元。截至2024年9月30日,現金及現金等價物爲730萬美元。該公司實現了重要的臨牀里程碑,包括在2024年8月爲ATR-12在Netherton綜合徵的10億臨牀試驗給第一位患者用藥,初步安全結果預計在2025年第一季度公佈。此外,Azitra在2024年9月獲得了FDA對ATR-04的快速通道認定,並計劃在2024年第四季度對接受EGFRi治療的癌症患者開始10億臨牀試驗。研發費用上升了85%,達到100萬美元,因爲公司推進了其臨牀項目。管理層指出了公司作爲持續經營能力的重大疑慮,提到需要額外的資金來支持未來12個月的運營。該公司在2024年7月完成了一次後續發行,通過售賣普通股和Warrants籌集了910萬美元。
Azitra報告了2024年第三季度的財務結果,淨虧損爲100萬美元,相較於2023年第三季度的190萬美元。營業收入爲零,而去年同期爲310,700美元,營業費用因臨牀項目推進增長了27%,達到290萬美元。截至2024年9月30日,現金及現金等價物爲730萬美元。該公司實現了重要的臨牀里程碑,包括在2024年8月爲ATR-12在Netherton綜合徵的10億臨牀試驗給第一位患者用藥,初步安全結果預計在2025年第一季度公佈。此外,Azitra在2024年9月獲得了FDA對ATR-04的快速通道認定,並計劃在2024年第四季度對接受EGFRi治療的癌症患者開始10億臨牀試驗。研發費用上升了85%,達到100萬美元,因爲公司推進了其臨牀項目。管理層指出了公司作爲持續經營能力的重大疑慮,提到需要額外的資金來支持未來12個月的運營。該公司在2024年7月完成了一次後續發行,通過售賣普通股和Warrants籌集了910萬美元。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
評論 評論 · 瀏覽 364

熱點推薦

聲明

本頁的譯文內容由軟件翻譯。富途將竭力但卻不能保證翻譯內容之準確和可靠,亦不會承擔因任何不準確或遺漏而引起的任何損失或損害。